{
  "abstract": "The aim of this study is to report pregnancy and infant outcomes in women with MS exposed to ocrelizumab before or during pregnancy and/or breastfeeding.Pregnancies from the Roche safety database were analysed. Maternal ocrelizumab exposure was defined as ≥1 infusion; in utero exposure was defined as an infusion ≤3 months prior to the last menstrual period (LMP) or during pregnancy. Major congenital anomalies (MCA) were classified via EUROCAT 1.5.As of 28 March 2024, 3,989 cumulative MS pregnancies were reported; A total of 1,000 prospective pregnancies were considered in utero exposed. In utero exposed and non-exposed groups with known outcomes had similar proportions of live births (LB) (85.8% vs 89.2%), including preterm (8.5% vs 8.1%) LB, and spontaneous abortion (6.9% vs 8.4%). The proportion of LB with MCA was similar between the exposed and non-exposed group (1.8% vs 1.5%) and remained within epidemiological background.In utero exposure to ocrelizumab, primarily occurring ≤3M before the LMP and first trimester, did not increase the risk of adverse pregnancy or infant outcomes. Counselling remains important to ensure optimal outcomes for mothers and infants.ruth.dobson@qmul.ac.uk",
  "authors": [
    {
      "affiliations": [
        "Centre for Preventive Neurology, Wolfson Institute of Population Health, QMUL"
      ],
      "name": "Dobson Ruth"
    },
    {
      "affiliations": [
        "Service de Neurologie et Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Lyon"
      ],
      "name": "Vukusic Sandra"
    },
    {
      "affiliations": [
        "Department of Neurology, UCSF Weill Institute for Neurosciences, UCSF"
      ],
      "name": "Bove Riley"
    },
    {
      "affiliations": [
        "Katholisches Klinikum Bochum, St. Josef Hospital,Universitätsklinikum, Bochum"
      ],
      "name": "Hellwig Kerstin"
    },
    {
      "affiliations": [
        "Division of Neurology, BARLO MS Centre, St. Michael’s Hospital, University of Toronto"
      ],
      "name": "Krysko Kristen"
    },
    {
      "affiliations": [
        "Department of Clinical Sciences and Community Health, University of Milan"
      ],
      "name": "Pietrasanta Carlos"
    },
    {
      "affiliations": [
        "Division of Maternal-Fetal Medicine, Brigham and Women’s Hospital, Boston"
      ],
      "name": "McElrath Thomas"
    },
    {
      "affiliations": [
        "F. Hoffmann-La Roche Ltd, Basel, Switzerland"
      ],
      "name": "Pasquarelli Noemi"
    },
    {
      "affiliations": [
        "Neurology, Hospital Clínico San Carlos, Idissc, Madrid"
      ],
      "name": "Oreja-Guevara Celia"
    }
  ],
  "title": "196 Pregnancy and infant outcomes in women with MS receiving ocrelizumab: analysis of ~4,000 pregnancies",
  "uid": "1baf8ed0-fe40-5faf-a196-6e273bd93cac"
}